Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects

Autor: Lemasson, Benjamin, Christen, Thomas, Tizon, Xavier, Farion, Régine, Fondraz, Nadège, Provent, Peggy, Segebarth, Christoph, Barbier, Emmanuel, Genne, Philippe, Duchamp, Olivier, Remy, Chantal
Přispěvatelé: Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Oncodesign [Dijon], Institut National du Cancer, Région Rhône-Alpes, Cancéropôle Lyon Auvergne Rhône-Alpes
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Zdroj: NMR in Biomedicine
NMR in Biomedicine, Wiley, 2011, 24 (5), pp.473-82. ⟨10.1002/nbm.1611⟩
ISSN: 0952-3480
1099-1492
Popis: International audience; Early imaging or blood biomarkers of tumor response is needed to customize anti-tumor therapy on an individual basis. This study evaluates the sensitivity and relevance of five potential MRI biomarkers. Sixty nude rats were implanted with human glioma cells (U-87 MG) and randomized into three groups: one group received an anti-angiogenic treatment (Sorafenib), a second a cytotoxic drug [1,3-bis(2-chloroethyl)-1-nitrosourea, BCNU (Carmustine)] and a third no treatment. The tumor volume, apparent diffusion coefficient (ADC) of water, blood volume fraction (BVf), microvessel diameter (vessel size index, VSI) and vessel wall integrity (contrast enhancement, CE) were monitored before and during treatment. Sorafenib reduced tumor CE as early as 1 day after treatment onset. By 4 days after treatment onset, tumor BVf was reduced and tumor VSI was increased. By 14 days after treatment onset, ADC was increased and the tumor growth rate was reduced. With BCNU, ADC was increased and the tumor growth rate was reduced 14 days after treatment onset. Thus, the estimated MRI parameters were sensitive to treatment at different times after treatment onset and in a treatment-dependent manner. This study suggests that multiparametric MR monitoring could allow the assessment of new anti-tumor drugs and the optimization of combined therapies. Copyright © 2010 John Wiley & Sons, Ltd.
Databáze: OpenAIRE
Externí odkaz: